Trial Profile
A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux) in Subjects With Advanced or Metastatic Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 754807 (Primary) ; Cetuximab (Primary)
- Indications Colorectal cancer; Head and neck cancer; Solid tumours
- Focus Adverse reactions
- 09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual initiation date changed from Oct 2009 to Nov 2007 as reported by ClinicalTrials.gov.
- 29 Sep 2011 Planned end date changed from 1 Jul 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.